Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity

Mov Disord. 2022 Mar;37(3):651-652. doi: 10.1002/mds.28929. Epub 2022 Jan 22.

Nurit Omer^{1

2

3}, Nir Giladi^{1

2

4}, Tanya Gurevich^{1

2

4}, Anat Bar-Shira⁵, Mali Gana-Weisz⁶, Tal Glinka⁶, Orly Goldstein⁶, Meir Kestenbaum⁷, Jesse M Cedarbaum^{8

9}, Omar S Mabrouk⁸, Kyle B Fraser⁸, Julia C Shirvan⁸, Avi Orr-Urtreger^{2

6}, Anat Mirelman^{2

3

4}, Avner Thaler^{1

2

3

4}

¹ Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
² Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
³ Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
⁴ Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv, Israel.
⁵ Genetic Institute, Tel-Aviv Medical Center, Tel-Aviv, Israel.
⁶ Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel-Aviv, Israel.
⁷ Neurology Department, Meir Medical Center, Kfar-Saba, Israel.
⁸ Biogen Inc, Cambridge, Massachusetts, USA.
⁹ Coeruleus Clinical Sciences LLC, Woodbridge, Connecticut, USA.

No abstract available

Publication types